|
|
|
|
| LEADER |
01618 am a22002533u 4500 |
| 001 |
95510 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Han, Sunkyu
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemistry
|e contributor
|
| 100 |
1 |
0 |
|a Movassaghi, Mohammad
|e contributor
|
| 100 |
1 |
0 |
|a Han, Sunkyu
|e contributor
|
| 700 |
1 |
0 |
|a Morrison, Karen C.
|e author
|
| 700 |
1 |
0 |
|a Hergenrother, Paul J.
|e author
|
| 700 |
1 |
0 |
|a Movassaghi, Mohammad
|e author
|
| 245 |
0 |
0 |
|a Total Synthesis, Stereochemical Assignment, and Biological Activity of All Known (−)-Trigonoliimines
|
| 260 |
|
|
|b American Chemical Society (ACS),
|c 2015-02-25T15:39:40Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/95510
|
| 520 |
|
|
|a A full account of our concise and enantioselective total syntheses of all known (−)-trigonoliimine alkaloids is described. Our retrobiosynthetic analysis of these natural products enabled identification of a single bistryptamine precursor as a precursor to all known trigonoliimines through a sequence of transformations involving asymmetric oxidation and reorganization. Our enantioselective syntheses of these alkaloids enabled the revision of the absolute stereochemistry of (−)-trigonoliimines A, B, and C. We report that trigonoliimines A, B, C and structurally related compounds showed weak anticancer activities against HeLa and U-937 cells.
|
| 520 |
|
|
|a National Institute of General Medical Sciences (U.S.) (GM074825)
|
| 520 |
|
|
|a EMD Serono, Inc. (Graduate Fellowship)
|
| 520 |
|
|
|a Kenneth Gordon Summer Fellowship
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Journal of Organic Chemistry
|
